Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
for Metastatic Malignant Solid Neoplasm
Drug: Olaparib
7 locations incl. Phoenix
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04585958·Phase 1·Recruiting